Antibe Therapeutics Inc. (“Antibe”) (TSXV:ATE, OTCQX:ATBPF) filed its financial and operating results today for the fiscal quarter ended December 31, 2014. The Corporation’s unaudited Q3...
Antibe Therapeutics Inc. (“Antibe” or the “Corporation”) (TSXV: ATE; OTCQX: ATBPF) is pleased to report results from animal proof-of-concept studies on ATB-352, which is the second drug in...
Antibe Therapeutics Inc. (“Antibe” or the “Corporation”) (TSXV:ATE; OTCQX:ATBPF) is pleased to report that the pre-scheduled single ascending dose portion of its Phase I program has been...
Antibe Therapeutics Inc. (“Antibe” or the “Corporation”) (TSXV:ATE; OTCQX:ATBPF) is pleased to report the results of the voting on the matters submitted to the annual meeting of shareholders...
OTC Markets Group Welcomes Antibe Therapeutics to OTCQX® PR Newswire NEW YORK, Sept. 15, 2014 NEW YORK, Sept. 15, 2014 /PRNewswire/ -- OTC Markets Group Inc. (OTCQX: OTCM), operator of Open...
Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
26 | 0 | 0 | 0.2156 | 0.2156 | 0.2156 | 0 | 0 | CS |
52 | -0.5047 | -70.0680272109 | 0.7203 | 0.8425 | 0.1113 | 25381 | 0.41093326 | CS |
156 | -0.2874 | -57.1371769384 | 0.503 | 0.8855 | 0.1113 | 13738 | 0.47387099 | CS |
260 | -0.11334 | -34.4561318174 | 0.32894 | 5.88 | 0.1113 | 80838 | 0.63501231 | CS |
Aucune Discussion Trouvée |
Ajouter une Discussion |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales